VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York. He gave Oncology Times reporter Sarah Maxwell his review of the clinical usefulness of targeting the CDK 4-6, PIK3CA and FGFR pathways.
You may also like...
Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers 19 Nov, 2013 Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia 10 Dec, 2007
ASCO Audio Journal of Oncology in Advance – February 1st, 2007 – reporting from American Society of Hematology 48th Annual Meeting, December 9-12, 2006 Orlando 3 Feb, 2007 International Research and Consensus Needed to Interpret Breast Cancer Genomics Data 27 Mar, 2015
- Previous story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- Next story No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014